From the Food and Drug Administration.
Nightingale
S L
SL
Office of Health Affairs, FDA, Rockville, MD 20857, USA.
D000329:Advertising / Q000592:standards*; D000767:Anesthesia, Epidural / Q000009:adverse effects*; D000775:Anesthesia, Spinal / Q000009:adverse effects*; D000925:Anticoagulants / Q000009:adverse effects*; D001562:Benzimidazoles / Q000009:adverse effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D000075202:Contraindications; D004347:Drug Interactions; D004348:Drug Labeling; D006406:Hematoma / Q000209:etiology*; D006493:Heparin / Q000009:adverse effects*; D006496:Heparinoids / Q000009:adverse effects*; D006801:Humans; D020748:Mibefradil; D013129:Spinal Puncture / Q000009:adverse effects*; D013764:Tetrahydronaphthalenes / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
D000925:Anticoagulants; D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D006496:Heparinoids; D013764:Tetrahydronaphthalenes; D020748:Mibefradil; D006493:Heparin